Nu-Med Plus (NUMD) Cash from Operations Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) Cash from Operations Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.94 Bn | 176.64 Bn | 6.27 Bn | 4.78% |
| 2 | Stryker | 128.78 Bn | 125.90 Bn | 3.81 Bn | 9.30% |
| 3 | Medtronic | 109.01 Bn | 99.79 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 68.59 Bn | 67.13 Bn | 3.61 Bn | 22.35% |
| 5 | Edwards Lifesciences | 47.66 Bn | 43.99 Bn | 1.29 Bn | -48.14% |
| 6 | GE HealthCare Technologies | 28.36 Bn | 26.07 Bn | 1.98 Bn | -14.75% |
| 7 | Dexcom | 28.30 Bn | 27.18 Bn | 750.30 Mn | 50.11% |
| 8 | Smith & Nephew | 26.93 Bn | 26.36 Bn | - | - |
| 9 | Koninklijke Philips | 25.45 Bn | 22.33 Bn | 2.07 Bn | 0.50% |
| 10 | Nu-Med Plus | 1.67 Mn | 1.67 Mn | - | -12.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -12.79% |
| Sep 30, 2025 | -172.24% |
| Dec 31, 2024 | 56.43% |
| Jun 30, 2024 | 67.34% |
| Mar 31, 2024 | 82.16% |
| Dec 31, 2023 | 60.83% |
| Sep 30, 2023 | 42.84% |
| Jun 30, 2023 | 46.10% |
| Mar 31, 2023 | 40.39% |
| Dec 31, 2022 | 41.91% |
| Sep 30, 2022 | 26.17% |
| Jun 30, 2022 | 72.39% |
| Mar 31, 2022 | 63.36% |
| Dec 31, 2021 | 47.99% |
| Sep 30, 2021 | 34.05% |
| Jun 30, 2021 | 12.61% |
| Mar 31, 2021 | 1.04% |
| Dec 31, 2020 | 20.00% |
| Sep 30, 2020 | 7.55% |
| Jun 30, 2020 | -18.03% |